Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics (Q43751494)

26 November 2017

title

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics (English)

1 reference

26 November 2017

Surinder Kaur

1 reference

26 November 2017

Keyang Xu

1 reference

26 November 2017

Ola M Saad

1 reference

26 November 2017

Randall C Dere

1 reference

26 November 2017

Montserrat Carrasco-Triguero

1 reference

26 November 2017

publication date

1 January 2013

1 reference

26 November 2017

1 reference

26 November 2017

1 reference

26 November 2017

1 reference

26 November 2017

page(s)

201-226

1 reference

Drug-conjugated monoclonal antibodies for the treatment of cancer

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Antibody-drug conjugates: targeted drug delivery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Progress in immunoconjugate cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Arming antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Antibody conjugate therapeutics: challenges and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Antibody-drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Targeted cancer therapy: conferring specificity to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Pharmacokinetic considerations for antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Bioanalysis of recombinant proteins and antibodies by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Contribution of linker stability to the activities of anticancer immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Recent developments in the maytansinoid antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Semisynthetic maytansine analogues for the targeted treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

Tumor-Specific Novel Taxoid−Monoclonal Antibody Conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.299

21 January 2018

Identifiers

DOI

10.4155/BIO.12.299

1 reference

26 November 2017

1 reference